Abcam, ab254345, Anti-beta Amyloid 1-40 antibody [EPR23712-2]

Size: 20µL / 100µL / 1mL
Anti-beta Amyloid 1-40 antibody [EPR23712-2] (ab254345) is a rabbit monoclonal antibody detecting beta Amyloid 1-40 in Western Blot, IHC-P, ELISA, Dot Blot . Suitable for Human . - Biophysical QC for unrivalled batch-batch consistency
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR23712-2,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:I-ELISA, WB, Dot, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
What is this antibody validated in?
Anti-beta Amyloid 1-40 antibody [EPR23712-2] (ab254345) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunohistochemistry (IHC-P), ELISA, Dot Blot in Human samples.
What is the molecular weight of beta Amyloid 1-40?
Anti-beta Amyloid 1-40 [EPR23712-2] (ab254345) specifically detects a band for beta Amyloid 1-40 (UniProt: P05067) at a molecular weight of 86kDa.
Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl.
Discover our selection of trial-size antibodies
Other related products
We have a range of other formats of antibody clone [EPR23712-2] also available for your convenience: ab254345, Carrier free -
ab289991
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Beta Amyloid 1-40 also known as amyloid beta 40 is a peptide predominantly composed of 40 amino acids and it is a major product of amyloid precursor protein (APP) cleavage. Its molecular mass is approximately 4.3 kDa. This peptide is expressed in the brain tissue and cerebrospinal fluid. Beta amyloid engages in forming amyloid plaques which are deposits found most typically in the brain of patients with neurodegenerative conditions.
Biological function summary
Small soluble oligomers of beta amyloid interact with neuronal cells leading to synaptic dysfunction and cell death. Beta amyloid 1-40 molecules do not normally function in isolation; they often assemble into beta amyloid plaques a complex structure that can contribute to cellular anomalies. Amyloid beta production and its aggregation play parts in a process that disrupts neural communication impacting memory and learning processes.
Pathways
The amyloidogenic pathway involves beta amyloid where amyloid precursor protein (APP) is cleaved by beta-secretase and gamma-secretase to generate beta amyloid peptides including amyloid beta 40. This molecule is associated with the oxidation and inflammation pathways where it can interact with other proteins like presenilin. Presenilin is a part of the gamma-secretase complex that influences amyloid production thereby affecting the pathological aggregation process.
Beta amyloid 1-40 is closely linked to Alzheimer's disease a condition marked by cognitive decline and neural loss. The presence of amyloid plaques which are high in amyloid beta content is a characteristic marker of this disease. Furthermore beta amyloid is also associated with cerebral amyloid angiopathy a disorder where the peptide accumulates in the walls of the cerebral blood vessels. In this context tau protein another Alzheimer's-associated protein shows pathological changes influenced by the beta amyloid-induced plaque formation and contributes to neurofibrillary tangles formation.